Regeneron Pharmaceuticals, Inc. REGN
788.04
(7.98)
(1.00%)
as of 25 Sep
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Regeneron Pharmaceuticals, Inc. (REGN) Net income
Regeneron Pharmaceuticals, Inc.'s net income for fiscal 2025 was $4.5B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $4.3B. Over the past ten years it has ranged from $636.1M (fiscal 2015) to $8.1B (fiscal 2021); the current reading is higher than 91% of that period. Regeneron Pharmaceuticals, Inc. ranks 2nd of 614 Biotechnology companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | $4.5B | 2.09% |
| FY2024 | $4.4B | 11.61% |
| FY2023 | $4.0B | (8.87%) |
| FY2022 | $4.3B | (46.28%) |
| FY2021 | $8.1B | 129.86% |
| FY2020 | $3.5B | 66.05% |
| FY2019 | $2.1B | (13.44%) |
| FY2018 | $2.4B | 103.95% |
| FY2017 | $1.2B | 33.84% |
| FY2016 | $895.5M | 40.79% |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $1.3B | 78.34% |
| Mar 2026 | $727.2M | (13.90%) |
| Dec 2025 | $844.6M | (42.15%) |
| Sep 2025 | $1.5B | 4.92% |
| 42 more quarters | Free account |
Against its own ten years
Low $636.1M
High $8.1B
Ten-year median
$3.5B
Current reading's percentile
91
Net income against peers
| Company | Net income |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | $4.4B |
| REGN Regeneron Pharmaceuticals, Inc. | $4.3B |
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $774.7M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $655.7M |
| INSM Insmed, Inc. compare | −$875.3M |
| RVMD Revolution Medicines, Inc. compare | −$1.8B |
| MRNA Moderna, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on REGN
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement